Oseltamivir Phosphate Capsules.

Effects and efficacy:
For the treatment of influenza A and B in adults and children aged 1 year and over. For the prevention of influenza A and B in adults and adolescents aged 13 years and over.

Dosage and administration:
For the treatment of influenza, treatment should be started on the first or second day (ideally within 36 hours) of the onset of influenza symptoms. Adults and adolescents over 13 years old: The recommended oral dose is 75 mg each time, twice a day, for 5 days. Please follow the doctor’s advice for details. Children over 1 year old: The dosage is given according to body weight (taken for 5 days), please follow the doctor’s advice for details. For those with body weight ≤ 15kg, 30 mg each time, twice a day; for those with body weight 15kg < body weight < 23kg, 45 mg each time, twice a day; for those with body weight 23kg < body weight < 40kg, 60 mg each time, twice a day; for those with body weight > 40kg, 75 mg each time, twice a day. Elderly: Generally, there is no need to adjust the dosage. Please follow the doctor’s advice for details. For the prevention of influenza, this product should be started within 2 days after close contact with influenza patients. The recommended oral dose is 75 mg once a day for at least 7 days. Please follow your doctor’s advice for details. For the prevention of influenza during the influenza season, the recommended dose is 75 mg once a day. Data show that continuous use of the drug for 6 weeks is safe and effective, and it has a preventive effect during the medication period. Please follow your doctor’s advice for details. The medication instructions for patients with renal insufficiency need to adjust the dosage according to the patient’s creatinine clearance; the pharmacokinetics of this product in patients with end-stage renal disease on dialysis have not been studied; therefore, no recommendations can be made for the dosage of such patients. 1. For patients with creatinine clearance > 60 ml/min for influenza treatment, there is generally no need to adjust the dosage. Please follow your doctor’s advice for details. For patients with creatinine clearance ≤ 60 ml/min and 30 ml/min, the recommended dose is reduced to 30 mg each time, twice a day, for a total of 5 days. Please follow your doctor’s advice for details. For patients with creatinine clearance ≤ 30 ml/min and 10 ml/min, 30 mg each time, once a day, for a total of 5 days. Please follow your doctor’s advice for details. For patients with regular hemodialysis, if the flu symptoms worsen within 48 hours during dialysis, 30 mg can be given before the start of dialysis. In order to maintain the blood concentration at the therapeutic level, a dose of 30 mg should be given after each dialysis. Please follow the doctor’s advice for details. For patients with peritoneal dialysis, it is recommended to give 30 mg of this product before the start of dialysis, and then give 30 mg every 5 days for treatment. Please follow the doctor’s advice for details. 2. For influenza prevention, patients with creatinine clearance>60ml/min do not need to adjust the dose; those with creatinine clearance of 30ml/min<≤60m/min, 30 mg each time, once a day; those with creatinine clearance of 10ml/min<≤30ml/min, 30 mg each time, once every other day; for patients with regular hemodialysis, if the flu symptoms worsen within 48 hours during dialysis, 30 mg can be given before the start of dialysis, and 30 mg can be given after every two dialysis sessions; for patients with peritoneal dialysis, it is recommended to give 30 mg of this product before the start of dialysis, and then give 30 mg every 7 days for prevention. Please follow the doctor's advice for details. Note: No dosage adjustment is required for the treatment and prevention of influenza in patients with mild to moderate hepatic insufficiency. However, the safety and pharmacokinetics of the drug in patients with severe hepatic insufficiency have not been studied; therefore, there is no recommended dosage for such patients. Adverse reactions: Common adverse reactions (incidence greater than 1%): gastrointestinal diseases, such as nausea and vomiting; nervous system diseases, such as headache; systemic diseases, such as pain. Other adverse reactions: dermatitis, rash, toxic epidermal necrolysis, Stevens-Johnson syndrome, etc.; arrhythmia; gastrointestinal bleeding; hepatitis or elevated liver enzymes; convulsions, delirium, hallucinations, nightmares, anxiety, etc. Drug contraindications: Contraindicated if allergic to this product